We are doing this study to learn more about the experimental treatment AZD0486, to learn if the study drug will be safe, tolerable and effective in treating the type of lymphoma that you have. AZD0486 is a ‘bispecific’ antibody. An antibody is a Y shaped protein used by your body’s immune system to identify and destroy natural foreign objects such as bacteria, viruses and proteins. A bispecific antibody is an antibody that interacts with two different molecules in your body. In the case of AZD0486, one molecule is called CD19 that is found on your lymphoma cells. The second molecule is called CD3 and is present on your T-cells.
A T-cell is a type of white blood cell that plays an important role in the immune system. T- cells are like soldiers that search out and destroy virus infected cells, foreign cells, and cancer cells. When CD3 is engaged on a T-cell, it turns the T-cell on and makes it kill whatever cell triggered the activation. Because AZD0486 sticks very strongly to your lymphoma cells, nearby T-cells should specifically attack your tumor (lymphoma) cells.
In this study we also want to better understand your lymphoma and associated health problems.
All parts of this study are experimental which means that AZD0486 has not been approved by any health authority that regulates new medicines such as the United States (US) Food and Drug Administration (FDA) or the European Medicines Agency (EMA), except for use in research studies like this. Please discuss all the treatment options available to you with your study doctor. AZD0486 is currently being developed for use in cancer patients and has been tested in some people in research studies like this.